Stereotactic ablative radiotherapy is associated with “clinically acceptable” rates of toxicity, local control, progression-free survival, and overall survival in people with oligometastatic cancer, meta-analysis data suggest.
Real-world lung cancer screening rates are generally much lower than those reported in randomized controlled trials, particularly when shorter screening intervals are used, US study findings indicate.
Patients with metastatic non-small-cell lung cancer may benefit from the combination of radiotherapy and pembrolizumab, suggests a pooled analysis of two randomized controlled trials.
Researchers have identified an association between the development of multisystem immune-related adverse events and improved survival outcomes in immune checkpoint inhibitor-treated patients with advanced non-small-cell lung cancer.
The phase 2 NADIM study points to the potential of neoadjuvant treatment with nivolumab plus platinum-based chemotherapy in treatment-naïve patients with resectable, stage IIIA non-small-cell lung cancer.
Combining a PD-L1 inhibitor with an etoposide–platinum chemotherapy regimen may be the optimal first-line treatment for patients with extensive-stage small-cell lung cancer, network meta-analysis findings suggest.
Older patients with non-small-cell lung cancer who have not progressed on platinum-based doublet therapy do not gain an overall survival advantage if treated with switch maintenance therapy rather than observation, study findings show.
CheckMate 9LA trial findings indicate that a front-line nivolumab plus ipilimumab-based regimen slows the decline in health-related quality of life for advanced non-small-cell lung cancer patients compared with chemotherapy alone.
CHRYSALIS trial findings suggest that the bispecific monoclonal antibody amivantamab could be combined with the third-generation EGFR–tyrosine kinase inhibitor lazertinib for the treatment of patients with metastatic or unresectable non-small-cell lung cancer with an EGFR exon 19 deletion or L858R mutation.
Treatment with pembrolizumab has led to a near doubling of the 5-year overall survival rate relative to chemotherapy among previously untreated patients with PD-L1-high, metastatic non-small-cell lung cancer, report the KEYNOTE-024 investigators.
Two phase 2 studies presented at the ESMO Virtual Congress 2020 have highlighted the risks and benefits of neoadjuvant immunotherapy in patients with resectable non-small-cell lung cancer.
First-line treatment with lorlatinib significantly improves progression-free survival, relative to crizotinib, in patients with advanced ALK-positive, non-small-cell lung cancer, results of the phase 3 CROWN study show.
Chemotherapy-naïve patients with nonsquamous non-small-cell lung cancer and EGFR-activating mutations derive prolonged progression-free survival from the addition of apatinib to gefitinib, phase 3 ACTIVE data show.
A progression-free survival of at least 12 months is a strong indicator of good survival outcomes at 2 years in patients with extensive-stage small-cell lung cancer taking durvalumab alongside first-line platinum–etoposide, even in those with poor prognostic factors, analysis of CASPIAN data shows.
Cemiplimab monotherapy offers a significant overall survival benefit compared with platinum-doublet chemotherapy for advanced non-small-cell lung cancer patients with a PD-L1 tumor cell expression of 50% or above, indicate initial EMPOWER-Lung 1 trial findings.
Adjuvant treatment with osimertinib substantially reduces the risk for central nervous system recurrence among patients with resected stage IB–IIIA EGFR-mutated non-small-cell lung cancer, shows an analysis of phase 3 study data.
Patients with completely resected stage IIIA N2 non-small-cell lung cancer do not benefit from postoperative radiotherapy, show the results of the phase 3 Lung ART trial presented at the ESMO Virtual Congress 2020.